Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007448 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
A Phase 4 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT01007448 is a Phase 4 study that has completed, run by Bausch Health Americas. The registered enrollment target is 59 participants.
The verdict
NCT01007448, a Phase 4 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
Interventions
- DRUG Bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-01-06 |
| Est. Completion | 2014-02-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01007448
The ClinicalTrials.gov registry entry for NCT01007448 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bexarotene is the first listed.
NCT01007448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01007448 about?
NCT01007448 is a clinical study titled "Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)". This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
What is the current status of trial NCT01007448?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2010-01-06. Estimated completion is 2014-02-20.
What interventions are being tested in trial NCT01007448?
The interventions under investigation include: Bexarotene (DRUG).
Who is sponsoring clinical trial NCT01007448?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.